Home › Funds › T. Rowe Price Investment Management, Inc. › ALNY
T. Rowe Price Investment Management, Inc. position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
T. Rowe Price Investment Management, Inc. reported holding 10,007,828 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$2.47B, representing 1.74% of its reported portfolio and ranking #7 among its reported holdings. T. Rowe Price Investment Management, Inc. has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How T. Rowe Price Investment Management, Inc.'s ALNY position evolved
T. Rowe Price Investment Management, Inc. first disclosed a stake in ALNY in Q3 2023 at 3,398,859 shares (US$601.9M). The position peaked in Q3 2026 at 10,007,828 shares, worth US$2.47B. Across 13 filings, T. Rowe Price Investment Management, Inc. increased the stake 7 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 10,007,828 shares valued at US$2.47B — an increase of 4,365,655 shares quarter over quarter.. Notable position changes include a 49% trim in Q3 2025 (shares fell 13% over the following quarter), a 196% increase in Q1 2026 (shares fell 8% over the following quarter), a 77% increase in Q3 2026 (shares fell 35% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 3.40M | $601.94M | New |
| Q4 2023 | 3.43M | $655.78M | Add |
| Q1 2024 | 2.87M | $429.36M | Reduce |
| Q2 2024 | 3.15M | $766.33M | Add |
| Q3 2024 | 3.14M | $863.39M | Hold |
| Q4 2024 | 4.38M | $1.03B | Add |
| Q1 2025 | 4.42M | $1.19B | Add |
| Q2 2025 | 4.28M | $1.40B | Reduce |
| Q3 2025 | 2.17M | $991.34M | Reduce |
| Q4 2025 | 1.75M | $697.34M | Reduce |
| Q1 2026 | 5.19M | $1.72B | Add |
| Q2 2026 | 5.64M | $1.70B | Add |
| Q3 2026 | 10.01M | $2.47B | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in ALNY — the largest reported positions include Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$597.4M), TWO SIGMA ADVISERS, LP (US$450.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 2.42M sh · $597.40M · Q3 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
More on T. Rowe Price Investment Management, Inc.
FAQ
How long has T. Rowe Price Investment Management, Inc. held ALNY?
T. Rowe Price Investment Management, Inc. has disclosed ALNY holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is T. Rowe Price Investment Management, Inc.'s current position in ALNY?
As of Q3 2026, T. Rowe Price Investment Management, Inc. holds 10.01M shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $2.47B, representing 1.74% of its reported portfolio and ranking #7.
Has T. Rowe Price Investment Management, Inc. been buying or selling ALNY?
In the latest 13F filing (Q3 2026), T. Rowe Price Investment Management, Inc. increased its position in ALNY. The position peaked in Q3 2026 at 10.01M shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include Baillie Gifford & Co, Orbis Allan Gray Ltd, TWO SIGMA ADVISERS, LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.